With fibroblast growth factors and their receptors being increasingly studied and taking into account their role in cancer-directed therapy, in this study we report the development of specific human antibody fragments, targeting fibroblast growth factor 1, that act as FGF1 ligand traps. This evidence concerns the gene FGF1 and cancer.